OBILET
4.8.2021 11:02:07 CEST | Business Wire | Press release
obilet.com, Turkey’s premier online travel ticketing platform, is set to enjoy rapid growth in the wake of the Covid-19 pandemic. Having just acquired its arch-rival Biletall, Obilet is forecast to sell more than 20 million tickets in 2021 – up from 8 million in 2020 – and close out the year with $300 million GMV.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210804005055/en/
Thanks to its unique offerings and innovative business model, the Istanbul-based travel-tech firm is now poised to expand its geographic reach amid an expected post-Covid global recovery.
SaaS-Powered Business Model
Already known throughout the region for its enormously popular ticket-booking app, Obilet’s primary distinction lies in its SaaS (Software-as-a-Service) powered business model. Obilet, invested in by EarlyBird and EBRD, provides bus operators with a best-in-class Ticket Management System (TMS) featuring 24/7 technical support. The company thereby creates a “lock-in effect” for its business operations on the supply side.
By distributing its portfolio of bus operators using its SaaS to other online ticketing platforms on a revenue-sharing basis, Obilet adds additional revenue streams on top of its lucrative B2C sales.
One of the world’s top-10 platforms for online bus and flight tickets, obilet.com saw remarkable growth in the pre-Covid-19 2016-2019 period, boasting a compound annual growth rate (CAGR) of 77%.
Biletall Buyout Cements Leading Position
Earlier last month (July 12), Obilet cemented its regional position by acquiring Biletall, its chief B2C and B2B competitor, which since the 2000s had played a pioneering role in the digitalization of Turkey’s travel industry. Although Obilet stole the top spot from Biletall in 2016 on the B2C side, Biletall nevertheless retained its leading position at B2B coverage.
The acquisition will give Obilet 100% destination coverage in one of the world’s largest bus markets, and the biggest in Europe. Turkey’s intra-state bus market currently generates some 200 million ticket sales per year, corresponding to roughly $3 billion annually.
Currently, more than 300 bus operators compete in this highly fragmented market, which remains largely unconsolidated despite the 2019 acquisition of the country’s largest domestic bus operator by Flix.
Plans for Expansion in Post-Covid Era
Obilet now is equipped with plug-and-play B2B and SaaS solutions to be offered to both operators and online/offline ticket resellers in neighboring countries, where there is huge revenue potential for the Turkish start-up.
Obilet’s vastly enhanced market share, coupled with rising travel demand in the post-Covid era, is expected to yield 40 million ticket sales in 2022 and a GMV of over $500 million. Company officials even suggest that, as Obilet gradually expands into fresh markets, annual GMV could reach as much as $1 billion within the next few years.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005055/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vena Completes Acterys Acquisition to Accelerate Orchestrated Planning for the Microsoft Ecosystem26.3.2026 14:00:00 CET | Press release
The combination connects AI-driven financial and operational planning, analytics and execution across Microsoft Excel and Power BI, removing decision latency for Microsoft-centric enterprises. Vena, the AI-powered Orchestrated Performance Management platform purpose-built to fully amplify the Microsoft technology ecosystem, today announced it has completed its acquisition of Acterys, the leading Microsoft Power BI–based operational planning and app development platform. The move strengthens Vena’s Orchestrated Planning solution and begins phased integration of the two platforms. Modern enterprises are struggling to keep up with the volatility and dynamism of the markets they serve. Market drivers and signals shift rapidly, and the ability to assess, plan and execute with confidence and speed is more important than ever. These forces, combined with overwhelming data density and disparity, have created a new constraint: decision latency—the time between signal and action. As that gap wid
Nearly Half of Global C-Suites Plan U.S. Expansion Within 12 Months, as Supply Chain and Capital Access Drive Growth26.3.2026 14:00:00 CET | Press release
• 45% of C-level executives plan to establish a U.S. legal entity within the next 12 months; a further 27% say they will consider entry within two to three years • 65% cite supply chain or manufacturing efficiency as the primary driver for U.S. expansion • 88% identify federal and state tax reporting as the most burdensome area of U.S. compliance Nearly half (45%) of global C-suite leaders plan to establish a legal entity in the United States within the next 12 months, highlighting continued demand for access to the U.S. market. This finding from the latest research by CSC—the leading provider of global business administration and compliance solutions—demonstrates the U.S. continues to attract investment from around the world, even as companies face an increasingly complex regulatory landscape. CSC surveyed 300 C-level executives at large organizations headquartered in Europe, the U.K., Asia Pacific, and South America to examine global sentiment toward U.S. market entry, including expa
Lone Star Funds Completes Acquisition of Alliance Ground International26.3.2026 13:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has completed the acquisition of Alliance Ground International (“AGI”), a leading North American airport services provider. “We are excited to partner with the AGI management team to drive the business forward,” said Donald Quintin, Chief Executive Officer of Lone Star. “The company has a superior service offering and a track record of success across its integrated operations. We see opportunities to continue to invest in the business and its people to continue to grow its capabilities and ensure it remains best-in-class in delivering for the aviation industry.” “Today marks an important next step for AGI as we move forward in partnership with Lone Star,” said Jared Azcuy, Chief Executive Officer of AGI. “Our commitment to safety, reliability, and operational service excellence remains unchanged. This partnership strengthens our ability to deliver for our airline partners and reinforces that the
Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging26.3.2026 13:30:00 CET | Press release
The Phase 1 study of RLS-1496, the first human trial of a GPX4 (selective glutathione peroxidase 4) modulator, met its primary endpoint and also demonstrated a statistically significant relationship between target engagement and clinical improvement in psoriasis and atopic dermatitis RLS-1496 is a first-in-class disease-modifying mechanism targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases of aging A second study for RLS-1496 – a Phase 1b/2a study in actinic keratosis (precancerous skin lesions) – is underway in the United States, with completion expected later this year Rubedo CEO Frederick Beddingfield, III, MD, PhD, FAAD, to moderate panel on senescence and skin at the Dermatology Innovation Forum (DIF) during the American Academy of Dermatology (AAD) annual meeting on Thursday, March 26, at 1:05 pm MT in Denver Oral presentation of data accepted at the Society for Investigative Dermatology (SID) from May 13-16, 2026, in Chicago Rubedo L
GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe26.3.2026 13:30:00 CET | Press release
COMPASS is one of the largest public‑private partnerships under the European Union’s (EU) Innovative Health Initiative (IHI). The consortium aims to advance early detection and prediction of cardiotoxicity in cancer patients and cancer survivors. The initiative will leverage AI, advanced imaging, biomarkers, and integrated care pathways. GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI. Cardiovascular diseases are rising sharply among cancer patients and survivors, driven both by the increasing prevalence of pre‑existing cardiovascular conditions at diagnosis and by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom